RegenxBio Interim Data from Phase I/IIa Trial of RGX-314 for Wet AMD
RegenxBio (RGNX) announced interim data from the ongoing Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD). Here are the results as presented by the Company.
The results were presented by Jeffrey S. Heier, M.D., Co-President and Director . . .
This content is for paid subscribers.
Impacting News October 14, 2019